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Abstract: We present a Turkish family with two cousins (OC15 and OC15b) affected with syndromic
developmental delay, microcephaly, and trigonocephaly but with some phenotypic traits distinct
between them. OC15 showed asymmetrical skeletal defects and syndactyly, while OC15b presented
with a more severe microcephaly and semilobal holoprosencephaly. All four progenitors were
related and OC15 parents were consanguineous. Whole Exome Sequencing (WES) analysis was
performed on patient OC15 as a singleton and on the OC15b trio. Selected variants were validated by
Sanger sequencing. We did not identify any shared variant that could be associated with the disease.
Instead, each patient presented a de novo heterozygous variant in a different gene. OC15 carried a
nonsense mutation (p.Arg95*) in PORCN, which is a gene responsible for Goltz-Gorlin syndrome,
while OC15b carried an indel mutation in ZIC2 leading to the substitution of three residues by a
proline (p.His404_Ser406delinsPro). Autosomal dominant mutations in ZIC2 have been associated
with holoprosencephaly 5. Both variants are absent in the general population and are predicted to be
pathogenic. These two de novo heterozygous variants identified in the two patients seem to explain
the major phenotypic alterations of each particular case, instead of a homozygous variant that would
be expected by the underlying consanguinity.
Keywords: neurodevelopmental disease; clinical genetics; whole exome sequencing; consanguinity;
focal dermal hypoplasia; holoprosencephaly
1. Introduction
Case Description Here, we report two de novo mutations causing severe neurodevel-
opmental delay in two first degree cousins from a highly consanguineous family of Turkish
origin (Figure 1).
Patient 1 was a 10-year-old girl and single child of a healthy, consanguineous couple of
Turkish origin. The family had a history of non-syndromic intellectual disability and deaf-
ness, with several affected individuals for each trait. Prenatally, the mother was hospitalized
for a urinary tract infection. There was no history of polyhydramnios/oligohydramnios or
maternal diabetes. Patient 1 was born at term by normal vaginal delivery and the birth
was uneventful. Her birth weight and height were 3.1 kg (−0.53 SD) and 48 cm (−0.71 SD),
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respectively. Since birth, she presented with failure to thrive and neonatal hypotonia. Addi-
tionally, congenital hip dislocation was detected. At the six months follow-up, her weight
was 4.5 kg (−4.08 SD), height was 58.5 cm (−3.07 SD), and head circumference was 37.3 cm
(−4 SD). She showed several craniofacial dysmorphologies, including severe microcephaly,
trigonocephaly (with prominent metopic ridge), facial asymmetry, and other features,
such as low hairline, hypoplastic orbital ridges, up-slanting palpebral fissures, strabismus,
sparse eyebrows, prominent ears, gingival hyperplasia, and high palate (Figure 2 and
Table 1). Ocular examination revealed a minimal bilateral optic disc hypoplasia. Short
neck, sometimes with crusting of the skin, was also observed. In addition, she presented
with radial head dislocation, hypoplasia of the right clavicle, widely spaced nipples, ulnar
deviation of the fingers, and complete cutaneous syndactyly of the right 3rd and 4th fingers
with bony fusion of the distal phalanges, overlapping toes on both feet, and spasticity of
the lower limbs. She had thickened subcutaneous soft tissue on the proximal phalanges
(prominently second finger) of the left hand. The patient had focal dermal hypoplasia
in the left region of the neck, axillary region, and the middle region of her right, lower
limb. She had also hypo-hyperpigmented lesions in her back, pelvic region, and trunk
(not shown). The patient also had hypodontia. Brain magnetic resonance imaging (MRI)
revealed periventricular gliotic changes, thin corpus callosum, and moderate cerebellar
atrophy. She was severely delayed (no head control at four years) and suffered from
epilepsy. The seizures, which were generally triggered by fever, were amenable to multiple
drug regimens. She passed away at the age of 10 due to a respiratory infection. She was
considered compatible with Opitz C clinical spectrum. Previous genetic analyses included
a normal karyotype and a normal array comparative genomic hybridization (array CGH).
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Figure 1. Extended family pedigree showing the relations among all four progenitors, the two mothers being sisters, and 
the two fathers being cousins once removed. Patient 1’s parents are also cousins once removed (connected through a 
double bond). Patients 1 and 2 in black. Patient 2’s microcephalic sister in grey. Squared pattern: congenital deafness. 
Wavy pattern: intellectual disability. 
Figure 1. Extended fa ily pedigree sho ing the relations a ong al four progenitors, the two others being sisters, and
the two fathers being cousins once removed. Patien 1’s parents are also cousins once removed (connected through a double
bond). Patients 1 and 2 in black. Patient 2’s microcephalic sister in grey. Squared pattern: congenital deafness. Wavy pattern:
intellectual disability.




Figure 2. Pictures of patient 1. (A–D) Face, hand, and foot at age 9. Notice the asymmetry of the face, complete cutaneous 
syndactyly of the right second and third fingers, and overlapping toes. Thickened subcutaneous soft tissue on the proximal 
phalanges (prominently second finger) of the left hand (discoloration on the left hand due to traditional ‘red henna’). (E) 
Radial head dislocation. (F) Right hand radiograph showing distal phalangeal bone fusion of the third and fourth fingers 
at the age of 6. (G) Patient 1 at 9 years of age. Notice the generalized hypotonia. (H) Patient 1 at 6 years of age. Hyperemic, 
crusted skin lesions and focal dermal hypoplasia in her neck and axillary region and hypodontia are noticeable. 
Table 1. Summary of the clinical features observed in each patient. 
Phenotype HPO Term Patient 1 Patient 2 
Microcephaly HP:0000252 + + 
Trigonocephaly HP:0000243 + + 
Protruding ears HP:0000411 + + 
Upslanted palpebral fissure HP:0000582 + + 
Neurodevelopmental delay HP:0012758 + + 
Short stature HP:0004322 + + 
Muscular hypotonia HP:0001252 + + 
Low anterior hairline HP:0000294 + − 
Facial asymmetry HP:0000324 + − 
Sparse eyebrows HP:0045075 + − 
Underdeveloped supraorbital ridges HP:0009891 + − 
Strabismus HP:0000486 + − 
High palate HP:0000218 + − 
Hypodontia HP:0000668 + − 
Gingival overgrowth HP:0000212 + − 
Failure to thrive HP:0001508 + - 
Figure 2. Pictures of patient 1. (A–D) Face, hand, and foot at age 9. Notice the asymmetry of the face, complete cutaneous
syndactyly of the right second and third fingers, and overlapping toes. Thickened subcutaneous soft tissue on the proximal
phalanges (prominently second finger) of the left hand (discoloration on the left hand due to traditional ‘red henna’).
(E) Radial head dislocation. (F) Right hand radiograph showing distal phalangeal bone fusion of the third and fourth fingers
at the age of 6. (G) Patient 1 at 9 years of age. Notice the generalized hypotonia. (H) Patient 1 at 6 years of age. Hyperemic,
crusted skin lesions and focal dermal hypoplasia in her neck and axillary region and hypodontia are noticeable.
Table 1. Summary of the clinical features observed in each patient.
Phenotype HPO Term Patient 1 Patient 2
Microcephaly HP:0000252 + +
Trigonocephaly HP:0000243 + +
Protruding ears HP:0000411 + +
pslanted palpebral fissure HP:0000582 + +
Neurodevelopmental delay HP:0012758 + +
Short stature HP:0004322 + +
Muscular hypotonia HP:0001252 + +
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Table 1. Cont.
Phenotype HPO Term Patient 1 Patient 2
Low anterior hairline HP:0000294 + −
Facial asymmetry HP:0000324 + −
Sparse eyebrows HP:0045075 + −
Underdeveloped supraorbital ridges HP:0009891 + −
Strabismus HP:0000486 + −
High palate HP:0000218 + −
Hypodontia HP:0000668 + −
Gingival overgrowth HP:0000212 + −
Failure to thrive HP:0001508 + -
Dislocated radial head HP:0003083 + −
Ulnar deviation of finger HP:0009465 + −
3-4 finger syndactyly HP:0006097 + −
Hip dislocation HP:0002827 + −
Hypopigmented skin patches HP:0001053 + −
Focal dermal hypoplasia HP:0007510 + −
Seizures HP:0001250 + −
Semilobar holoprosencephaly HP:0002507 − +
Proptosis HP:0000520 − +
Retrognathia HP:0000278 − +
Tapered fingers (mild) HP:0001182 − +
Patient 2 was a first cousin of patient 1, sharing both the paternal and maternal
lineages (Figure 3 and Table 1). He was a four-year-old boy and the third child of healthy,
non-consanguineous Turkish parents. He was born at term by normal vaginal delivery
with a weight of 3.08 kg (−0.72 SD). The mother had had one abortus because of ectopic
pregnancy. One older sister (15 years old) presented with microcephaly (head circumference
of 50 cm at 13 years, <1st percentile, −3.44 SD), without intellectual disability. The other
sister (10 years old) was healthy. Patient’s 2 first examination was at 2 months. He was
in the normal range for weight (4.8 kg, −0.88 SD) and height (58 cm, 0.04 SD), but he
presented with microcephaly (Figure 3) with a head circumference under the first percentile
(33 cm, −4.82 SD). At this time, his muscle tone was normal. Follow up at 8.5 months
confirmed severe microcephaly (−4.58 SD), with semi-lobar holoprosencephaly and mild
trigonocephaly shown by cranial MRI. Additional dysmorphologies included retrognathia,
ocular proptosis, up-slanting palpebral fissures, prominent ears, mild tapering fingers,
proximal placement of thumb, and short stature (but within the range of his close family).
Eye, cardiac, and kidney examination at 8 months were normal. He presented with severe
delay in developmental milestones, such as poor head control. Previous genetic analyses
included normal karyotype and sequencing of KIF11, which showed no mutations. In
spite of some clear differences with his cousin (Table 1), shared phenotypes suggested the
presence of one common, major genetic cause for both patients.
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the head at age 4. Microcephaly, retrognatia, ocular proptosis and upslanting palpebral fissures are appreciable. (D,E) Foot 
and hands of the patient at age 4. 
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(above average). Assuming an autosomal recessive inheritance pattern, patient 1 dis-
played variants in 52 selected genes, while patient 2 presented variants in 12 selected 
genes (Supplementary Tables S1 and S2). None of these homozygous variants was clearly 
pathogenic. In contrast, each patient harboured a de novo variant in a known ID gene. 
Patient 1 was heterozygous for a de novo, previously described [2], pathogenic variant in 
PORCN (2)(MIM * 300651), p.Arg95* (X:48369829 C>T; ENST00000326194: c.283C>T), 
while patient 2 carried a novel de novo heterozygous mutation at the Zinc-finger protein 
of the cerebellum 2, ZIC2, gene (MIM * 603073, mutation p.His404_Ser406delinsPro). Both 
mutations and their de novo status were confirmed by Sanger sequencing in the patients 
and their parents (and the respective cousin). WES and the Sanger sequencing results sug-
gest that patient 1 is a mosaic for the PORCN p.Arg95* mutation. 
The nonsense mutation p.Arg95* in PORCN creates a premature STOP codon at po-
sition 95 of the 461 residue-long protein-serine O-palmitoleoyltransferase porcupine pro-
tein. The mutation lies in exon 2 of 14, which is, therefore, subject to the degradation of 
the mutated mRNA by nonsense-mediated decay (NMD). In addition, if translated, the 
truncated protein would lack the majority of functional domains, including the active site. 
Figure 3. Distinctive features of patient 2. (A,B) Frontal view of the face at ages 8 months and 4 years.
(C) Lateral view of the head at age 4. Microcephaly, retrognatia, ocular proptosis and upslanting
palpebral fissures are appreciable. (D,E) Foot and hands of the patient at age 4.
2. esults and iscussion
Scre ning for shared pathogenic variants betwe n the two cases was negative. Patient
1 showed large homozygous regions, as revealed by PLINK [1] analysis (5 fragments of
ore than 1 b of homozygosity, with a majority of fragments 2–6 Mb long), indicating
consanguinity, while patient 2 showed 20 fragments of more than 1Mb of homozygosity
(above average). ssu ing an autoso al recessive inheritance pattern, patient 1 dis-
played variants in 52 selected genes, while patient 2 presented variants in 12 selected
genes (Supplementary Tables S1 and S2). None of these ho ozygous variants was clearly
pathogenic. In contrast, each patient harboured a de novo variant in a known ID gene.
Patient 1 was heterozygous for a de novo, previously described [2], pathogenic variant
in PORCN (2)(MIM * 300651), p.Arg95* (X:48369829 C>T; ENST00000326194: c.283C>T),
while patient 2 carried a novel de novo heterozygous mutation at the Zinc-finger protein of
the cerebellum 2, ZIC2, gene (MIM * 603073, mutation p.His404_Ser406delinsPro). Both
mutations and their de novo status were confirmed by Sanger sequencing in the patients
and their parents (and the respective cousin). WES and the Sanger sequencing results
suggest that patient 1 is a mosaic for the PORCN p.Arg95* mutation.
The nonsense mutation p.Arg95* in PORCN creates a premature STOP codon at posi-
tion 95 of the 461 residue-long protein-serine O-palmitoleoyltransferase porcupine protein.
The mutation lies in exon 2 of 14, which is, therefore, subject to the degradation of the mu-
tated mRNA by nonsense-mediated decay (NMD). In addition, if translated, the truncated
protein would lack the majority of functional domains, including the active site. PORCN
mutations have been associated with Goltz-Gorlin Syndrome (or focal dermal hypoplasia,
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FDH, MIM #305600), transmitted as an X-linked dominant trait, and the p.Arg95* muta-
tion found in patient 1 had been identified in a 30 year-old woman also presenting with
linear skin lesions, asymmetrical skeletal defects, clinodactyly, dental defects, and micro-
cephaly [2]. However, there is no mention of developmental delay/intellectual disability
(DD/ID). Goltz-Gorlin Syndrome is a clinical entity with high phenotypic heterogeneity
and developmental delay, although rare, that is described in about 10%–15% of the pa-
tients [3–5]. In addition, patient 1 presented with the more frequently reported clinical
characteristics, including facial asymmetry, short stature, agenesis of the corpus callosum,
or moderate cerebellar atrophy. All this points to p.Arg95* in PORCN as a pathogenic
mutation and the main cause of the disorder observed in patient 1. PORCN is a key regula-
tor of the Wnt signalling pathway mediating the attachment of palmitoleate, a 16-carbon
monounsaturated fatty acid, to Wnt proteins. Serine palmitoleylation of Wnt proteins is
required for efficient binding to frizzled receptors and activation of Wnt signalling [6].
On the other hand, while patient 1 fits well in the FDH phenotypic entity, she has a
more severe level of DD than other reported cases. Therefore, we hypothesized that other
genetic factors might be contributing to her severe neurological presentation, especially
since other family members present with non-syndromic ID (Figure 1). Worthy of interest,
three variants were found in homozygosity in relevant genes (Supplementary Table S1): two
missense variants in NCAPD3 [c.3488C>T, p.(Pro1163Leu), rs143158496*] and in YY1AP1
[c.1858G>A; p.(Ala620Thr)], and a synonymous variant with a putative effect on splicing
in UFC1 (c.246C>T, p.Ile82=). The variant in NCAPD3, is present in public databases at a
very low frequency, although slightly higher in the Turkish population (gnomAD April
2020: 29 carriers out of 251446 alleles, no homozygotes, higher minor allele frequency
(MAF) 0.0009 for East Asian, GME Variome: 1/163, MAF:0.006, Turkish population), which
would be consistent with a recessive pattern of inheritance. NCAPD3 has been previously
related to microcephaly with moderate developmental delay [7], and a mouse model for
Ncapd2 (NCAPD3 partner) shows microcephaly as well. However, only 8 out of 18 in
silico predictors consider this change as putatively damaging and, while the NCAPD3
gene is constrained for loss of function (LoF) variants, it does not show constraint for
missense mutations (o/e = 1.07 at gnomAD). Therefore, this change is classified as a variant
of unknown significance (VUS), according to the American College of Medical Genetics
(ACMG) guidelines [8], but we cannot rule out its potential contribution to the severity
of the microcephaly and the DD traits of patient 1. Recessive LoF mutations in YY1AP1
associate with Grange syndrome (GRNG, MIM #602531), whose presentation includes
syndactyly and learning difficulties [9–11]. The variant is also present in public databases
(gnomAD 18 carriers out of 141388, highest MAF 0.00013, absent in GME Variome). Finally,
UFC1 is associated with “neurodevelopmental disorder with spasticity and poor growth”
(MIM #618076) [12] and the variant identified in patient 1 is present in public databases at
a very low frequency (gnomAD: 2 alleles out of 251490).
ZIC2 is a transcription factor involved both in activation and repression, which plays
a key role in the early stages of the central nervous system (CNS) development [13]. The
ZIC2 mutation detected in patient 2 involves the deletion of 7 bp and the insertion of
1 bp at the cDNA position 1211 [c.1211_1217delACCCCAGinsC (ENST00000376335)],
leading to the substitution of the three residues at positions 404 to 406 by a proline
(p.His404_Ser406delinsPro). This variant is not found in the general population (gno-
mAD, Iranome, and GME Variome) and residues 404 to 406 are fully conserved through
the 28 species analysed (Supplementary Figure S1). This variant is classified as pathogenic
following the ACMG guidelines [8]. The ZIC proteins are defined by the presence of a
zinc finger domain that consists of five Cys2His2-type zinc fingers and this change is in a
mutational hot-spot affecting the fifth C2H2-type Zinc Finger domain of the ZIC2 protein.
Autosomal Dominant (AD) mutations in ZIC2 have been associated with holoprosen-
cephaly 5 (HPE5, MIM #609637), characterized by severe neurological impairment, seizures,
and characteristic dysmorphic facies. These traits are consistent with the patient’s clinical
phenotype, who presented with semi-lobar holoprosencephaly and severe developmental
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delay (seizures have not been identified so far). While this specific mutation has not been
previously reported, other non-frameshift mutations affecting the same domain have been
identified in HPE5 patients [14–17], including the substitution of His 404 by Arg [15].
In conclusion, we have classified the ZIC2 heterozygous mutation as likely pathogenic,
and as the disease-causing mutation responsible for the major phenotypic alterations of
the patient.
Other changes that can contribute to the patient’s phenotype have also been evaluated
(Supplementary Table S2). In particular, the patient and his two sisters are homozygous
for mutation p.Tyr1073Cys in CFTR (7:117251713 A>G, ENST00000003084: c.3218A>G,
p.Tyr1073Cys). This gene encodes an epithelial ion channel that mediates the transport of
chloride ions. Autosomal Recessive (AR) mutations in it are associated with cystic fibrosis
(CF, MIM #219700), sweat chloride elevation without CF, and congenital bilateral absence
of vas deferens (CBAVD, MIM #277180). The same mutation identified in this family had
been previously identified in a patient with neonatal hypertrypsinaemia without lung
disease and is included in the Cystic Fibrosis Mutation database. This mutation is absent in
the common population (gnomAD, Iranome, and GME Variome) and it is predicted to be
damaging for the protein performance by most functional prediction algorithms. We have
considered this variant to be likely pathogenic, according to the ACMG guidelines [8], and
have recommended detailed clinical assessment of the patient and his sisters. In addition to
the de novo ZIC2 mutation, Patient 2 is a homozygote for the KPNA7 p.Arg217Trp mutation
(7:98786174 G>A, ENST00000327442: c.649C>T, Supplementary Table S2), inherited from
his parents (both heterozygotes). The healthy sister does not carry the mutant allele, while
the sister affected by microcephaly is also homozygous for this change. This variant
is rare in the common population (only 27 carriers, no homozygotes, in gnomAD) and
algorithms developed to predict the effect of missense changes on protein structure and
function (SIFT, PolyPhen2, PROVEAN, or Mutation assessor) do not agree on the potential
impact of this missense change. KPNA7 recessive mutations have been associated with
infantile spasms and cerebellar malformation only once in the literature [18]. These authors
presented a pair of sibs affected with severe developmental disability, infantile spasms,
intractable epilepsy consistent with Lennox–Gastaut syndrome, partial agenesis of the
corpus callosum, and cerebellar vermis hypoplasia in which two heterozygous KPNA7
mutations have been identified by WES. In these patients, microcephaly was not present
(with head circumference at the 98th and 50th percentiles). In conclusion, this variant is
classified as likely benign and does not seem to be related to the patient’s clinical phenotype,
but its implication on moderate microcephaly cannot be ruled out without further studies.
Both causal genes that mutated in these cousins (PORCN and ZIC2) encode proteins
that are directly implicated in the Wnt pathway. The mechanistic coincidence on these two
factors could explain some of the clinical similarities among these patients, both harbouring
mutations in genes that, prima facie, seem not to be related. Wnt signalling pathways
regulate complex normal biological processes such as cell differentiation, development,
tissue homeostasis, and wound healing. However, when the Wnt pathway is aberrantly
regulated, it can be associated with bone anomalies, neurodevelopmental disorders, cancer,
and cardiovascular diseases, among other diseases [19]. Wnt signalling is a particularly
complex pathway that leads to the activation of two main, alternative branches: the canoni-
cal and the noncanonical pathway. In the canonical pathway, the binding of Wnt proteins
to their receptors (Frizzled and Lrp5/6) triggers the inactivation or disassembly of the
destruction complex, which reduces β-catenin phosphorylation and promotes its accumu-
lation and translocation to the nucleus. There, β-catenin forms a complex with Lef/Tcf
factors and induces the transcription of specific genes. Activation of the noncanonical
pathway does not depend on β-catenin-driven transcription. Instead, it relies on changes
that affect cytoskeletal organization and calcium homeostasis [19]. PORCN (protein-serine
O-palmitoleoyltransferase porcupine) mediates palmitoylation of Wnt proteins, which is
an essential modification necessary for their correct secretion and binding to the Frizzled
receptors, thus, being a major regulator of Wnt signalling [20–22]. On the other hand, Zic
Int. J. Mol. Sci. 2021, 22, 1549 8 of 10
genes are implicated in development of the dorsal neural tube and neural crest as well as
the somites and the cerebellum. In addition to the regulation of multiple neural factors,
ZIC2 functions as a modulator of Wnt signalling by the direct interaction with TCF4 [23] or
by modulating β-catenin accumulation and activity [24].
3. Materials and Methods
Patient 1 was included in the URDCat genetic program and underwent whole exome
sequencing (WES) analysis as previously described [25,26] (briefly, sequencing was done at
the CNAG facility using the Nimblegen SeqCap EZ MedExome + mtDNA 47Mb capture kit
aiming at 90× coverage). Patient 2 was analyzed by trio-WES, briefly, (samples from patient
2 and his parents were also sequenced at the CNAG facility). In this case, capture was
performed with Agilent SureSelect v5 (Agilent, CA, USA). The samples were sequenced at
a coverage of 140×. Basic bioinformatic processing of the sequencing data was performed
using CNAG’s in-house pipeline. Annotation and filtering for both cases was performed
with VarAFT [26]. All variants included in Tables S1 and S2 were analysed by Sanger
sequencing in the patient, mother, and father, as well as in her affected cousin. Primers
and conditions used for PCR amplification and sequencing are available on demand.
Sequence alterations are reported according to the Human Genome Variation Society
(HGVS) nomenclature guidelines. The gnomAD (v.2.1.1), Iraniome, and Great Middle East
Variome databases were accessed on May 2020.
4. Conclusions
Two main considerations arise from this study. In the first place, while in Western
countries syndromic and non-syndromic DD and ID are mainly sporadic and caused by de
novo mutations [27], in the near and Great Middle East, where there is a high consanguinity
rate [28], ID is commonly due to recessive mutations [29]. When presented with highly
consanguineous families segregating a disease phenotype, one of the first approaches is
to search for pathogenic mutations in homozygosity tracks. In addition, performing WES
analysis only on the index case is a common practice, which, in highly consanguineous
populations, yields acceptable diagnostic results [30]. While the cost advantage of such an
approach is evident, it is important to keep in mind that, even in cases with a very high
consanguinity, de novo disease causing mutations may still be present, representing up to
27.8% of the ID mutations identified in these families [29] when trio-WES is performed. It
should not be forgotten that these mutations are still one of the major causes of ID. Thus,
to avoid misdiagnosis, we strongly recommend trio-WES or, if unavailable, a cautious
revision of putative dominant mutations (likely followed by segregation analysis of a
higher number of putative candidates) even in these families. In the present study, WES of
patient 1 was followed by segregation analysis of up to 16 heterozygous variants, while
the trio-WES of patient 2 involved further checking of only six variants. Otherwise, we
risk basing our diagnosis solely on putatively pathogenic homozygous variants in the
detriment of undetected de novo mutations also present in the patient.
The second important consideration from this study is the co-occurrence of multiple
genetic diseases in the same individual, leading to a very complex phenotype. This can
be especially likely in families with high levels of consanguinity, potentially segregating
various pathogenic mutations [31].
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